PATIENCE JOHN 4

What Happened
John Patience, Chairman and a director of Biodesix (BDSX), reported the vesting/conversion of 1,361 restricted stock units (RSUs) into 1,361 shares on June 30, 2026. The Form 4 records the derivative conversion under transaction code M (exercise/conversion of a derivative). The entries show no cash exchanged (price reported as $0.00 and total value $0), indicating these were vesting/settlement events rather than open-market purchases or sales.

Key Details

• Transaction date: 2026-06-30; Form 4 filed: 2026-07-02 (filed within the typical 2-business-day window).
• Reported transactions: 1,361 shares acquired via conversion of derivative (RSU) and an associated derivative disposition recorded at $0.00.
• Price/Value: $0.00 reported for the disposition; no cash consideration shown.
• Shares owned after the transaction: not specified in this filing.
• Footnotes:
  • F1: Each RSU equals a contingent right to one share.
  • F4: These RSUs vest in four equal installments (Mar 31, Jun 30, Sep 30, Dec 31, 2026) and have no expiration date — this was the June 30 vesting installment.
  • F2/F3: Reporting person has interests through Patience Enterprises LP and a living trust and disclaims beneficial ownership except to the extent of pecuniary interest.

Context
This was a compensation-related vesting/settlement of RSUs, not a market purchase or sale. The filing does not show any immediate open-market sale of the shares (no cashless exercise or sale reported). Such vesting events are routine executive compensation and do not by themselves indicate a buy or sell signal.